JP6458957B2 - Ｐｄｅ４阻害剤の製造方法 - Google Patents

Ｐｄｅ４阻害剤の製造方法 Download PDF

Info

Publication number
JP6458957B2
JP6458957B2 JP2016519348A JP2016519348A JP6458957B2 JP 6458957 B2 JP6458957 B2 JP 6458957B2 JP 2016519348 A JP2016519348 A JP 2016519348A JP 2016519348 A JP2016519348 A JP 2016519348A JP 6458957 B2 JP6458957 B2 JP 6458957B2
Authority
JP
Japan
Prior art keywords
formula
compound
ether
isopropyl
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016519348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505752A (ja
Inventor
ファルチ，アレッサンドロ
ルテロ，エミリオ
フェラーリ，エマヌエーレ
ピヴェッティ，ファウスト
ブッソラーティ，ロッコ
マリアーニ，エドアルド
ヴェッキ，オルソラ
バッペルト，エアハルト
ヴェントリッチ，カテリーナ
Original Assignee
チエシ ファルマスティスィ エス．ピー．エー．
チエシ ファルマスティスィ エス．ピー．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6458957(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by チエシ ファルマスティスィ エス．ピー．エー．, チエシ ファルマスティスィ エス．ピー．エー． filed Critical チエシ ファルマスティスィ エス．ピー．エー．
Publication of JP2017505752A publication Critical patent/JP2017505752A/ja
Application granted granted Critical
Publication of JP6458957B2 publication Critical patent/JP6458957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016519348A 2013-10-22 2014-10-17 Ｐｄｅ４阻害剤の製造方法 Active JP6458957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13189784.5 2013-10-22
EP13189784 2013-10-22
PCT/EP2014/072334 WO2015059050A1 (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189627A Division JP2019038813A (ja) 2013-10-22 2018-10-05 Ｐｄｅ４抑制活性を有する化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2017505752A JP2017505752A (ja) 2017-02-23
JP6458957B2 true JP6458957B2 (ja) 2019-01-30

Family

ID=49385193

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016519348A Active JP6458957B2 (ja) 2013-10-22 2014-10-17 Ｐｄｅ４阻害剤の製造方法
JP2018189627A Pending JP2019038813A (ja) 2013-10-22 2018-10-05 Ｐｄｅ４抑制活性を有する化合物の結晶形態
JP2020173216A Active JP7051970B2 (ja) 2013-10-22 2020-10-14 Ｐｄｅ４抑制活性を有する化合物の製造方法
JP2022025300A Active JP7534346B2 (ja) 2013-10-22 2022-02-22 Ｐｄｅ４抑制活性を有する化合物の製造方法
JP2022025240A Active JP7345581B2 (ja) 2013-10-22 2022-02-22 Ｐｄｅ４抑制活性を有する化合物の製造方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018189627A Pending JP2019038813A (ja) 2013-10-22 2018-10-05 Ｐｄｅ４抑制活性を有する化合物の結晶形態
JP2020173216A Active JP7051970B2 (ja) 2013-10-22 2020-10-14 Ｐｄｅ４抑制活性を有する化合物の製造方法
JP2022025300A Active JP7534346B2 (ja) 2013-10-22 2022-02-22 Ｐｄｅ４抑制活性を有する化合物の製造方法
JP2022025240A Active JP7345581B2 (ja) 2013-10-22 2022-02-22 Ｐｄｅ４抑制活性を有する化合物の製造方法

Country Status (29)

Country Link
US (8) US9434691B2 (enExample)
EP (5) EP3587400B1 (enExample)
JP (5) JP6458957B2 (enExample)
KR (3) KR102240865B1 (enExample)
CN (5) CN105658629B (enExample)
AR (4) AR098128A1 (enExample)
AU (1) AU2014339136C1 (enExample)
BR (1) BR112016008161B1 (enExample)
CA (3) CA3115570C (enExample)
CY (1) CY1123811T1 (enExample)
DK (3) DK3587400T3 (enExample)
ES (3) ES2759514T3 (enExample)
FI (1) FI3587400T3 (enExample)
HR (3) HRP20240783T1 (enExample)
HU (3) HUE067681T2 (enExample)
IL (4) IL285528B2 (enExample)
LT (2) LT3587400T (enExample)
MX (4) MX389002B (enExample)
MY (1) MY182559A (enExample)
PH (3) PH12021550257A1 (enExample)
PL (3) PL3060551T3 (enExample)
PT (3) PT3587400T (enExample)
RS (2) RS65452B1 (enExample)
RU (1) RU2682660C9 (enExample)
SG (4) SG10201903575UA (enExample)
SI (3) SI3293176T1 (enExample)
TW (3) TWI651305B (enExample)
UA (2) UA121853C2 (enExample)
WO (1) WO2015059050A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022071008A (ja) * 2013-10-22 2022-05-13 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４抑制活性を有する化合物の製造方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024922B1 (ru) 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
US20190275022A1 (en) * 2016-07-20 2019-09-12 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
US20250288568A1 (en) 2022-04-27 2025-09-18 Chiesi Farmaceutici S.P.A. New crystal form of a pde4 inhibitor
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
CA3267958A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
AU2023347027A1 (en) 2022-09-22 2025-05-01 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
KR102925863B1 (ko) 2023-11-27 2026-02-09 국립한국해양대학교산학협력단 복수의 학습모델을 이용한 이미지 기반의 강도 추정 장치 및 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
WO2001074829A1 (en) * 2000-03-30 2001-10-11 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
WO2005026095A1 (en) * 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
ES2342083T3 (es) * 2004-04-29 2010-07-01 Aventis Pharmaceuticals Inc. 3-piperidinilisocroman-5-oles como agonistas de dopamina.
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
US8148537B2 (en) * 2006-12-22 2012-04-03 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN102939280B (zh) 2010-06-14 2014-11-19 奇斯药制品公司 格隆氯铵的晶型
EA024922B1 (ru) * 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
ES2628891T3 (es) * 2010-08-03 2017-08-04 Chiesi Farmaceutici S.P.A. Formulación farmacéutica que comprende un inhibidor de fosfodiesterasa
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
CN103827088B (zh) * 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia
CA2893628C (en) * 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
CN103304408B (zh) * 2013-06-05 2016-10-05 威海迪素制药有限公司 罗氟司特中间体3-环丙甲氧基-4-二氟甲氧基苯甲酸的制备
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
AU2014339136C1 (en) * 2013-10-22 2019-10-31 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
US20210038575A1 (en) * 2017-12-28 2021-02-11 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
CN118475343A (zh) * 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022071008A (ja) * 2013-10-22 2022-05-13 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４抑制活性を有する化合物の製造方法

Also Published As

Publication number Publication date
ES2759514T3 (es) 2020-05-11
DK3293176T3 (da) 2021-02-15
US10759761B2 (en) 2020-09-01
US20190345108A1 (en) 2019-11-14
JP2021011494A (ja) 2021-02-04
JP2017505752A (ja) 2017-02-23
EP3060551B1 (en) 2019-09-18
PT3293176T (pt) 2021-03-03
PL3060551T3 (pl) 2020-03-31
US10323003B2 (en) 2019-06-18
US9890122B2 (en) 2018-02-13
PH12016500737B1 (en) 2022-03-23
IL285528B2 (en) 2025-09-01
JP7345581B2 (ja) 2023-09-15
HUE067681T2 (hu) 2024-11-28
MX2022000030A (es) 2022-07-19
KR20210021415A (ko) 2021-02-25
IL285528B1 (en) 2025-05-01
AR122183A2 (es) 2022-08-24
CN105658629A (zh) 2016-06-08
CN114621139B (zh) 2025-06-20
ES2857629T3 (es) 2021-09-29
AR122182A2 (es) 2022-08-24
KR102240865B1 (ko) 2021-04-16
ES2980505T3 (es) 2024-10-01
PT3060551T (pt) 2019-12-09
PL3293176T3 (pl) 2021-06-28
EP3293176B1 (en) 2020-12-02
MX2022000036A (es) 2022-07-19
DK3587400T3 (da) 2024-04-02
SG10201903575UA (en) 2019-05-30
HRP20210336T1 (hr) 2021-04-16
KR102287598B1 (ko) 2021-08-11
CN110256338A (zh) 2019-09-20
BR112016008161B1 (pt) 2022-11-29
US20210040040A1 (en) 2021-02-11
IL245220A (en) 2017-06-29
AU2014339136B2 (en) 2018-05-31
CY1123811T1 (el) 2022-05-27
LT3293176T (lt) 2021-03-25
IL252834A0 (en) 2017-08-31
TWI720803B (zh) 2021-03-01
CA3115570C (en) 2024-01-30
MX370104B (es) 2019-12-02
HRP20192152T1 (hr) 2020-02-21
IL285532B2 (en) 2024-03-01
US20260159483A1 (en) 2026-06-11
TW201605804A (zh) 2016-02-16
US11352327B2 (en) 2022-06-07
FI3587400T3 (fi) 2024-06-20
JP2022068321A (ja) 2022-05-09
JP2019038813A (ja) 2019-03-14
IL252834B (en) 2021-09-30
KR102287596B1 (ko) 2021-08-11
RS61558B1 (sr) 2021-04-29
AR118124A2 (es) 2021-09-22
IL245220A0 (en) 2016-06-30
TWI685486B (zh) 2020-02-21
PH12016500737A1 (en) 2016-05-30
CN120136784A (zh) 2025-06-13
PH12020500162A1 (en) 2021-08-02
HUE053112T2 (hu) 2021-06-28
US11981639B2 (en) 2024-05-14
HUE046637T2 (hu) 2020-03-30
TW201904945A (zh) 2019-02-01
JP7051970B2 (ja) 2022-04-11
CN114621139A (zh) 2022-06-14
RU2682660C2 (ru) 2019-03-20
EP3587400A2 (en) 2020-01-01
SG11201603130TA (en) 2016-05-30
EP3060551A1 (en) 2016-08-31
CA2928242A1 (en) 2015-04-30
US20160326117A1 (en) 2016-11-10
US20240166605A1 (en) 2024-05-23
SI3587400T1 (sl) 2024-05-31
EP4059921A1 (en) 2022-09-21
JP7534346B2 (ja) 2024-08-14
TW202021952A (zh) 2020-06-16
SG10201912852YA (en) 2020-02-27
US20150111931A1 (en) 2015-04-23
DK3060551T3 (da) 2019-10-28
UA127453C2 (uk) 2023-08-30
CA3115587A1 (en) 2015-04-30
PT3587400T (pt) 2024-06-05
AU2014339136C1 (en) 2019-10-31
WO2015059050A1 (en) 2015-04-30
RU2016115246A3 (enExample) 2018-06-27
MX389002B (es) 2025-03-20
US9434691B2 (en) 2016-09-06
CN120607463A (zh) 2025-09-09
HRP20240783T1 (hr) 2024-09-27
KR20210021416A (ko) 2021-02-25
TWI651305B (zh) 2019-02-21
UA121853C2 (uk) 2020-08-10
PH12021550257A1 (en) 2023-01-23
US20180118686A1 (en) 2018-05-03
CA3115570A1 (en) 2015-04-30
IL285532B1 (en) 2023-11-01
RU2016115246A (ru) 2017-11-27
SG10202112587RA (en) 2021-12-30
PL3587400T3 (pl) 2024-07-01
MY182559A (en) 2021-01-25
HK1223926A1 (zh) 2017-08-11
US20220348545A1 (en) 2022-11-03
EP3587400B1 (en) 2024-03-20
AR098128A1 (es) 2016-05-04
MX2019014408A (es) 2020-01-27
EP3798209A1 (en) 2021-03-31
CN105658629B (zh) 2019-07-16
EP3293176A1 (en) 2018-03-14
SI3293176T1 (sl) 2021-04-30
MX2016004834A (es) 2016-07-19
JP2022071008A (ja) 2022-05-13
PH12020500162B1 (en) 2024-06-14
CA3115587C (en) 2026-01-06
KR20160072127A (ko) 2016-06-22
SI3060551T1 (sl) 2019-11-29
LT3587400T (lt) 2024-04-25
CA2928242C (en) 2022-03-15
BR112016008161A2 (enExample) 2017-08-01
IL285532A (en) 2021-09-30
KR102240865B9 (ko) 2021-12-13
IL285528A (en) 2021-09-30
RU2682660C9 (ru) 2019-06-21
RS65452B1 (sr) 2024-05-31
EP3587400A3 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
JP7534346B2 (ja) Ｐｄｅ４抑制活性を有する化合物の製造方法
AU2014339136A1 (en) Process for the preparation of a PDE4 inhibitor
HK40068745A (en) Process for the preparation of a pde4 inhibitor
HK40121266A (en) Process for the preparation of a pde4 inhibitor
HK40012263A (en) Process for the preparation of a pde4 inhibitor
HK1223926B (en) Process for the preparation of a pde4 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181211

R150 Certificate of patent or registration of utility model

Ref document number: 6458957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250